NCT02243202View on ClinicalTrials.gov

Effects of Co-administration of Canagliflozin 300 mg and Phentermine 15 mg With Placebo in the Treatment of Non-Diabetic Overweight and Obese Participants

PHASE2CompletedINTERVENTIONAL
Enrollment

335

Participants

Timeline

Start Date

September 30, 2014

Primary Completion Date

June 30, 2015

Study Completion Date

June 30, 2015

Conditions
Obesity
Interventions
DRUG

Canagliflozin

300 mg capsule, taken once daily, orally for 26 weeks.

DRUG

Phentermine

15 mg capsule, taken once daily, orally for 26 weeks.

DRUG

Matching Placebo to Canagliflozin

Placebo capsules look like canagliflozin but do not contain any active drug, taken once daily, orally for 26 weeks.

DRUG

Matching Placebo to Phentermine

Placebo capsules look like phentermine but do not contain any active drug, taken once daily, orally for 26 weeks.

Trial Locations (17)

Unknown

Phoenix

Walnut Creek

Jacksonville

Meridian

Evansville

Lexington

Louisville

New Orleans

Milford

Manlius

Warwick

Mt. Pleasant

Nashville

Dallas

Odessa

Norfolk

Wauwatosa

All Listed Sponsors
lead

Janssen Research & Development, LLC

INDUSTRY

NCT02243202 - Effects of Co-administration of Canagliflozin 300 mg and Phentermine 15 mg With Placebo in the Treatment of Non-Diabetic Overweight and Obese Participants | Biotech Hunter | Biotech Hunter